George K. Ng is CEO at Processa Pharmaceuticals, Inc. (PCSA). They have made 13 open-market trades across 2 companies since 2015, most recently 2026-08-08.
CIK 0001638744
12 open-market purchases totalling $2.1M since 2015, against 1 sale. Across 12 scored buys the stock is down 21.7% at ninety days, and 24.1 points behind the S&P over the same stretch.
12 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SRNE | 302,146 | $93K |
| PCSA | 17,092 | $29K |
| Total | $121K |
Shares reported on the most recent Form 4, priced at the 2026-08-11 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 17% | 25% | 0% |
| Avg Move | -9.6% | -11.9% | -21.7% |
| Alpha | -9.4% | -13.6% | -24.1% |
| Scored | 12 | 12 | 12 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCSA | BUY | 2026-07-01 | 2026-07-01 | $1.93 | $6K | +7.5% | +0.9% | -14.6% |
| PCSA | BUY | 2026-06-15 | 2026-06-16 | $2.22 | $5K | -7.5% | +5.7% | -10.4% |
| PCSA | BUY | 2026-05-29 | 2026-06-01 | $2.57 | $5K | -6.2% | -23.7% | -20.6% |
| PCSA | BUY | 2026-05-15 | 2026-05-19 | $2.97 | $5K | -2.7% | -18.4% | -18.0% |
| PCSA | BUY | 2026-04-30 | 2026-05-01 | $2.69 | $5K | -6.6% | -7.3% | -25.5% |
| PCSA | BUY | 2026-04-15 | 2026-04-17 | $2.97 | $5K | -17.2% | -16.9% | -32.3% |
| PCSA | BUY | 2026-03-31 | 2026-04-01 | $2.54 | $5K | +0.0% | -4.5% | -34.0% |
| PCSA | BUY | 2025-01-27 | 2025-01-29 | $0.80 | $70K | -9.7% | -21.5% | -67.2% |
| PCSA | BUY | 2024-01-30 | 2024-01-31 | $2.70 | $27K | +2.5% | +1.7% | -9.9% |
| SRNE | BUY | 2018-02-28 | 2018-02-28 | $9.95 | $1.8M | -18.9% | -52.7% | -21.4% |
| SRNE | SELL | 2017-02-03 | 2017-02-03 | $5.15 | $206K | +8.7% | -7.7% | -63.5% |
| SRNE | BUY | 2015-08-21 | 2015-08-21 | $13.50 | $12K | -28.1% | -3.2% | -3.2% |
| SRNE | BUY | 2015-08-03 | 2015-08-05 | $11.50 | $132K | -28.1% | -3.2% | -3.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.